BRD32048

TargetMol
Product Code: TAR-T23820
Supplier: TargetMol
CodeSizePrice
TAR-T23820-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-1mL1 mL * 10 mM (in DMSO)£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-5mg5mg£209.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-10mg10mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-25mg25mg£503.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-50mg50mg£695.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23820-100mg100mg£946.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
BRD32048 is a top candidate ETV1 perturbagen. BRD32048 inhibits p300-dependent acetylation of ETV1, thereby promoting its degradation.
CAS:
433694-46-3
Formula:
C16H22N6O
Molecular Weight:
314.393
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
COc1ccc(cc1)N=c1/nc(CN2CCCCC2)nc(N)[nH]1
Target:
DNA/RNA Synthesis

References

1. Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J Jr, Kaidi A, Malik K. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Lett. 2017 Sep 10;403:74-85. doi: 10.1016/j.canlet.2017.05.027. Epub 2017 Jun 7. PubMed PMID: 28602975; PubMed Central PMCID: PMC5542135. 2. Pop MS, Stransky N, Garvie CW, Theurillat JP, Hartman EC, Lewis TA, Zhong C, Culyba EK, Lin F, Daniels DS, Pagliarini R, Ronco L, Koehler AN, Garraway LA. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Mol Cancer Ther. 2014 Jun;13(6):1492-502. doi: 10.1158/1535-7163.MCT-13-0689. Epub 2014 Apr 15. PubMed PMID: 24737027; PubMed Central PMCID: PMC4154495.